Introduction
============

CD4^+^CD25^+^forkhead box (Fox)P3^+^ T-regulatory (Treg) cells are an important subset of immune cells that may inhibit the activation, proliferation and cytokine secretion of other types of immune cell. Treg cells have an indispensable role in driving autoimmune tolerance and maintaining the immune balance *in vivo* ([@b1-etm-0-0-7873]--[@b3-etm-0-0-7873]). Abnormal Treg cell functions are widely involved in the occurrence and development of numerous diseases ([@b4-etm-0-0-7873]--[@b6-etm-0-0-7873]), and immunotherapy to recover the number and/or function of Treg cells is a good optional treatment for such diseases.

Immunotherapy with transplanted Treg cells has been used in autoimmune diseases and other immune-associated diseases, including type-1 diabetes mellitus, systemic lupus erythematosus (SLE) and graft vs. host disease (GVHD) ([@b7-etm-0-0-7873]--[@b13-etm-0-0-7873]). Culturing sufficient numbers of Treg cells *in vitro* is the foundation of Treg-based immunotherapy, and maintaining the stable inhibitory function of Treg cells *in vivo* is pivotal for successful treatment ([@b8-etm-0-0-7873],[@b9-etm-0-0-7873]). However, the stability and inhibitory function of Treg cells in the internal inflammatory environment requires further systematic investigation.

The internal environment of patients with autoimmune diseases is complex and there may be inflammation or elevated levels of inflammatory cytokines, including tumour necrosis factor-α, interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-23 (IL-23) and interferon-γ (IFN-γ) expressed in human atherosclerotic plaques ([@b14-etm-0-0-7873],[@b15-etm-0-0-7873]); interleukin-17 (IL-17), IFN-γ, IL-6 and IL-23 expressed in type 1 diabetes mellitus ([@b16-etm-0-0-7873]); IL-1β and IL-17 expressed in SLE ([@b17-etm-0-0-7873]); and IL-6 expressed in GVHD ([@b9-etm-0-0-7873],[@b18-etm-0-0-7873]). IL-6 is the critical cytokine that mediates inflammation ([@b18-etm-0-0-7873],[@b19-etm-0-0-7873]). As mentioned above, IL-6 is highly expressed in autoimmune diseases and GVHD ([@b9-etm-0-0-7873],[@b14-etm-0-0-7873]--[@b16-etm-0-0-7873],[@b18-etm-0-0-7873]), and the inflammatory environment *in vivo* may be simulated by adding IL-6.

In the present study, the possible inflammatory environment was simulated *in vitro* by using recombinant human (rh)IL-6 to observe the absolute number, stability, activity and inhibitory function of Treg cells. The present study lays a foundation for Treg cell-based immunotherapy in various diseases.

Materials and methods
=====================

### Samples

A total of eight healthy blood donors were recruited from Shaanxi Provincial People\'s Hospital Affiliated to Xi\'an Medical University (Xi\'an, China); the male/female ratio was 4:4, and the average age was 27.8±1.3 years. A total of 40 ml sterile peripheral venous blood samples (including heparin to prevent clotting) were collected from all healthy blood donors. The study was approved by the Ethics Committee of Xi\'an Medical University (Xi\'an, China; approval no. XYLS2019131). According to the principle of informed consent, all healthy blood donors signed consent forms prior to collection of the peripheral blood samples. All of the experiments in this study were performed in accordance with the guidelines for blood sample collection approved by the Institutional Ethics Committee of Xi\'an Medical University.

### Isolation of peripheral blood mononuclear cells (PBMCs)

PBMCs were isolated from the samples via density-gradient centrifugation. First, 20 ml of Lymphoprep™ (Axis-Shield) was added to each centrifuge tube, and then, 20 ml of the individual peripheral blood sample diluted with an equal volume of PBS was slowly added. After centrifugation for 20 min at 500 × g under room temperature, the centrifuge tubes were gently removed and the monocyte suspension was isolated and washed with PBS. After the erythrocytes were lysed with FACS lysis solution (BD Biosciences), the isolated PBMCs were washed with PBS and then resuspended in PBS and counted.

### Sorting of Treg cells and T-effector (Teff) cells

After 4×10^7^ PBMCs were resuspended in RPMI 1640 Media supplemented with 10% fetal bovine serum and 100 U/ml penicillin and 100 mg/ml streptomycin (All Gibco; Thermo Fisher Scientific, Inc.), peridinin chlorophyll (PerCP)-conjugated anti-CD4 (cat. no. 347324, BD Biosciences) and allophycocyanine (APC)-conjugated anti-CD25 antibodies (cat. no. 555434, BD Biosciences) were added both at a dilution of 1:5 with the final concentration of PBMCs at 1×10^6^/100 µl. Another 1×10^6^ PBMCs were resuspended in media mentioned above, PerCP-conjugated Mouse IgG1 κ Isotype Control (cat. nos. 559425, BD Biosciences) and APC-conjugated Mouse IgG1 κ Isotype Control (cat. no. 555751, BD Biosciences) were added at a dilution of 1:5 with the final concentration of PBMCs at 1×10^6^/100 µl. After incubation with the antibodies at 4°C protected from light for 20 min, the PBMCs were washed with PBS and resuspended in fully supplemented RPMI 1640 Medium. After filtration with a cell strainer (Falcon; BD Biosciences), the stained PBMCs were processed with a BD FACS Aria II (BD Biosciences) and the CD4^+^CD25^high^ Treg cells and CD4^+^CD25^−^ Teff cells were sorted. CD25^−^ cells were defined using the isotype control antibody and CD25^high^ cells were defined according to a previous reported protocol ([@b20-etm-0-0-7873]).

### In vitro culture of Treg cells

rhIL-2 and anti-CD3/CD28 beads (Dynabeads^®^ Human T-Expander CD3/CD28 beads; Life Technologies; Thermo Fisher Scientific, Inc.) are necessary for the culturing of Treg cells *in vitro*, since IL-2 signals are required for the maintenance of lineage stability, survival and suppressor function in mature Tregs, whilst CD3 and CD28 signaling is crucial for the survival and proliferation of Treg cells ([@b21-etm-0-0-7873]--[@b23-etm-0-0-7873]). Freshly sorted Treg cells were cultured (1×10^5^/well) in a 96-well U-bottomed plate in the presence of 100, 300 or 500 U/ml rhIL-2 (HumanZyme; ProteinTech Group, Inc.) and anti-CD3/CD28 beads (Treg cells/beads ratio, 0.5:1, 1:1 or 2:1), with or without 25 ng/ml rhIL-6 (HumanZyme) under 37°C in a humidified atmosphere containing 5% CO~2~. The cell concentration was 1×10^6^/ml and 100 µl/well. The Treg cell population was counted after culturing for 3, 5, 7, 10 and 14 days, the medium was replaced after culturing for 3, 5, 7 and 10 days with RPMI 1640 Media supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and corresponding concentrations of rhIL-2 and rhIL-6.

### Stability and activity of Treg cells

Treg cells were collected after culturing for 3, 5, 7, 10 and 14 days. After the cells were washed and resuspended in PBS, PerCP-conjugated anti-CD4 and APC-conjugated anti-CD39 (cat. no. 560239; BD Biosciences) were added at a dilution of 1:5 with final concentration of cells at 1×10^6^/100 µl. The cells were then incubated with the antibodies at 4°C while protected from light for 20 min. The cells were then washed twice with PBS and treated for 30 min with 1 ml fixation/permeabilization buffers and washed three times with 2 ml permeabilization buffer (cat. no. 00-5523-00; Foxp3/transcription factor staining buffer set; eBioscience; Thermo Fisher Scientific, Inc.). Finally, the cells were washed twice with PBS and incubated at 4°C in the dark for 30 min with PE-conjugated anti-FoxP3 antibody (cat. no. 12-4777-42; eBioscience) at a dilution of 1:20. APC-conjugated Mouse IgG2b κ Isotype Control (cat. no. 555745; BD Biosciences) were used at a dilution of 1:5 and PE-conjugated Mouse IgG1 kappa Isotype Control (P3.6.2.8.1; cat. no. 12-4714-82; eBioscience) were used at a dilution of 1:20 in the staining procedures. After being washed twice with PBS and filtered using a cell strainer, the stained cells were processed using BD FACSCalibur (BD Biosciences) and the proportions of CD4^+^FoxP3^+^ Treg cells and CD39^+^CD4^+^FoxP3^+^ active Treg cells were analysed.

### Detection of inhibitory function of Treg cells

The inhibitory function of Treg cells was measured by detecting the suppression of Teff cell proliferation in the presence of Treg cells. Freshly sorted Teff cells were labelled with 5,6-carboxyfluorescein succinimidyl ester (CFSE; CellTrace™ CFSE Cell Proliferation Kit; Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. The labelled cells (1×10^5^/well) were cultured with or without sorted Treg cells (5×10^4^/well) in a 96-well U-bottomed plate in the presence of anti-CD3/CD28 beads (Teff cells/beads, 1:1), without or with 25 ng/ml rhIL-6. rhIL-2 was not added, as the Teff cells are able to secrete IL-2 after activation with anti-CD3/CD28 beads ([@b24-etm-0-0-7873]). The Teff cell proliferation was determined by flow cytometry after Teff cells were cultured for 5 days. The proliferation curves of the Teff cells were fitted, and the Teff-cell proliferation were expressed as the response (R; the proportion of the precursor sample pool that responded to stimulation by dividing), doubling time (Td; the time required for the average responding T cell to achieve a single cell division) and the proliferative capacity (Cp) of the responding T cells in each sample. The methodology for calculating R, Td and Cp from the proliferation curves was described in detail in previous studies ([@b24-etm-0-0-7873]--[@b26-etm-0-0-7873]).

### Statistical analysis

All flow cytometry results of the present study were analysed with FlowJo software version 7.6.1 (FlowJo LLC). Calculations were performed using GraphPad Prism software, version 6 (GraphPad Software, Inc). Values are expressed as the mean ± standard error of the mean, the significance of differences between two groups were calculated using paired t-test and Student\'s unpaired 2-tailed t-te\#st. The significance of differences among three groups was calculated using One-way ANOVA followed by Tukey\'s test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Sorting of Treg cells and Teff cells

After extracellular staining with PerCP-conjugated anti-CD4 and APC-conjugated anti-CD25, the freshly isolated PBMCs were processed with a BD FACS Aria II to sort the Treg cells and Teff cells (98.0% purity for each subset). The average proportion of CD4^+^CD25^high^ Treg cells in the lymphocyte population was 1.7±0.3% and the average proportion of CD4^+^CD25^high^ Treg cells in the CD4^+^ T-lymphocyte population was 5.3±0.8%. The average proportion of CD4^+^CD25^−^ Treg cells in the lymphocyte population was 23.1±3.3% and the average proportion of CD4^+^CD25^high^ Treg cells in the CD4^+^ T-lymphocyte population was 72.2±2.8% ([Fig. 1](#f1-etm-0-0-7873){ref-type="fig"}).

### Optimum concentration of rhIL-2 and anti-CD3/CD28 beads for culture of Treg cells

The absolute counts of Treg cells cultured with 100, 300 or 500 U/ml rhIL-2 for 14 days in the presence of anti-CD3/CD28 beads (Treg cells/beads, 1:1) *in vitro* are presented in [Fig. 2A](#f2-etm-0-0-7873){ref-type="fig"}. The number of Treg cells was 1×10^5^/well on day 0, except for the experiment for detection of inhibitory function. The number of Treg cells increased steadily until reaching a plateau \~day 10 after culturing *in vitro*. There were no differences among the counts of Treg cells cultured with 100, 300 or 500 U/ml rhIL-2 for 3 or 5 days. There was a significant difference between the counts of Treg cells cultured with 100 and 300 U/ml rhIL-2 for 7, 10 or 14 days. There was no difference between the counts of Treg cells cultured with 300 and 500 U/ml rhIL-2 for 7, 10 or 14 days.

The absolute counts of the Treg cells cultured for 14 days with anti-CD3/CD28 beads (Treg cells/beads, 0.5:1, 1:1 or 2:1) in the presence of 300 U/ml rhIL-2 *in vitro* are presented in [Fig. 2B](#f2-etm-0-0-7873){ref-type="fig"}. The Treg cell counts also increased with culture time until plateauing \~day 10. There were no differences among the counts of Treg cells cultured *in vitro*, whether the ratio of cells to beads was 0.5:1, 1:1 or 2:1 during culture for 3 or 5 days. There was a significant difference between the counts of Treg cells cultured with beads at a 0.5:1 cell-to-bead ratio and those cultured with beads at a 1:1 cell-to-bead ratio at 7, 10 or 14 days. There was no difference in the counts between Treg cells cultured with beads at a 1:1 ratio and those cultured with beads at a 2:1 ratio at 7, 10 or 14 days.

The above results demonstrate that the absolute count of the Treg cells is significantly affected by the concentration of rhIL-2 and anti-CD3/CD28 beads; 300 U/ml rhIL-2 and a 1:1 cell/bead ratio are the optimal concentrations when the Treg cells are cultured *in vitro*, and 3.17±0.10×10^5^ cells were obtained after 14 days of culture.

### The Treg cell number is reduced under inflammatory conditions

The absolute counts of Treg cells cultured for 14 days in the presence of rhIL-2 (300 U/ml) and anti-CD3/CD28 beads (Treg cells/beads, 1:1), without or with 25 ng/ml rhIL-6 *in vitro* are presented in [Fig. 3](#f3-etm-0-0-7873){ref-type="fig"}. There was no difference in the counts of Treg cells cultured without and with 25 ng/ml rhIL-6 when cultured for \<5 days *in vitro*. There was a significant difference in the counts of Treg cells cultured without and with 25 ng/ml rhIL-6 when cultured for \>7 days (P\<0.05). The number of Treg cells cultured in the presence of 25 ng/ml rhIL-6 for 14 days was reduced by 49.7% when compared with that of cells cultured without rhIL-6.

### The stability of Treg cells declines under inflammatory conditions

Treg cells were cultured (300 U/ml rhIL-2; Treg cells/beads, 1:1; without or with 25 ng/ml rhIL-6) for 14 days *in vitro*; the proportion of CD4^+^FoxP3^+^ Treg cells within the total cell population of the well (thereafter referred to as total cell population) and the FoxP3 mean fluorescence intensity (MFI) of CD4^+^FoxP3^+^ Treg cells are presented in [Fig. 4A and B](#f4-etm-0-0-7873){ref-type="fig"}, respectively. The proportion of CD4^+^FoxP3^+^ Treg cells was 98.0% on day 0, as the purity for sorted Treg cells was 98.0%. Regarding the proportion of CD4^+^FoxP3^+^ Treg cells within the total cell population, there was a significant difference in the proportion of CD4^+^FoxP3^+^ Treg cells cultured without and with 25 ng/ml rhIL-6 when cultured for 3, 5, 7, 10 and 14 days (P\<0.05). In terms of the FoxP3 MFI of CD4^+^FoxP3^+^ Treg cells, there was no difference between the cells cultured without and with 25 ng/ml rhIL-6, whether cultured for 3, 5, 7, 10 or 14 days *in vitro*.

Regarding the proportion of CD4^+^FoxP3^+^ cells within the total cell population cultured in the presence of rhIL-2, which gradually declined over the 14-day culture period, the proportion of Treg cells cultured with rhIL-6 decreased much faster compared with the proportion of Treg cells cultured without rhIL-6 ([Fig. 4A](#f4-etm-0-0-7873){ref-type="fig"}). Among the Treg cells cultured without rhIL-6, there were always certain amounts of cells expressing FoxP3, although the proportion declined gradually, and the proportion of CD4^+^FoxP3^+^ Treg cells within the total cell population was 56.2±2.7% after Treg cells were cultured for 14 days. However, FoxP3 expression decreased more rapidly in the Treg cells cultured with rhIL-6, and the proportion of CD4^+^FoxP3^+^ Treg cells within the total cell population was 24.7±3.4% after Treg cells were cultured for 14 days, which suggests a lower stability of Treg cells in the inflammatory environment and that increased numbers of Treg cells should be used in treatments considering the complexity of the internal environments of patients.

### The activity of Treg cells remains unchanged under inflammatory conditions

The activity of Treg cells was then investigated by detecting CD39 expression, as the expression of CD39 on T cells reflects high activity ([@b27-etm-0-0-7873]). The proportions of CD39^+^CD4^+^FoxP3^+^ active Treg cells in the CD4^+^FoxP3^+^ cell population after culture for 3, 5, 7, 10 or 14 days in the presence of rhIL-2 (300 U/ml) and anti-CD3/CD28 beads (Treg cells/beads, 1:1), without or with 25 ng/ml rhIL-6, are provided in [Fig. 5](#f5-etm-0-0-7873){ref-type="fig"}. Regarding the proportion of CD39^+^CD4^+^FoxP3^+^ Treg cells in the CD4^+^FoxP3^+^ cell population and the CD39 MFI of CD39^+^CD4^+^FoxP3^+^ Treg cells, there was no difference between the cells cultured without rhIL-6 and with 25 ng/ml rhIL-6, whether cultured for 3, 5, 7, 10 or 14 days *in vitro*.

The proportion of active Treg cells in the CD4^+^FoxP3^+^ cell population remained unchanged during the 14 days of culture *in vitro*, even under inflammatory conditions, which further proves the stability of the Treg-cell subset and provides a basis for the clinical application of Treg cells.

### The inhibitory function of Treg cells declines under inflammatory conditions

Finally, the suppressive function of Treg cells cultured without or with 25 ng/ml rhIL-6 was investigated by measuring their ability to suppress the Teff cell proliferation *in vitro*. After Treg and Teff cells were sorted from the PBMCs of healthy donors (n=8), the Teff cells were labelled with CFSE and co-cultured with Treg cells (Teff cells/Treg cells, 2:1) in the presence of anti-CD3/CD8 beads (Teff cells/beads, 1:1), without or with 25 ng/ml rhIL-6. Teff-cell proliferation was detected after culture for 5 days by gating on CFSE^+^ cells, and the results of the corresponding R, Td, and Cp measurements were presented in [Fig. 6](#f6-etm-0-0-7873){ref-type="fig"} ([@b24-etm-0-0-7873]--[@b26-etm-0-0-7873]).

The representative overlaid proliferation curve comparing Teff cells cultured alone and Teff cells co-cultured with Treg cells are presented in [Fig. 6A](#f6-etm-0-0-7873){ref-type="fig"}, the proliferation of Teff cells was inhibited when co-cultured with Treg cells, independent of rhIL-6 presence ([Fig. 6A](#f6-etm-0-0-7873){ref-type="fig"}). As presented in [Fig. 6B](#f6-etm-0-0-7873){ref-type="fig"}, the proportion of the precursor sample pool that responded to stimulation by dividing (R-value) did not change significantly when the Teff cells were co-cultured with Treg cells, regardless of rhIL-6 presence. In terms of the time required for the average responding T cell to achieve a single cell division the (Td value) shown in [Fig. 6C](#f6-etm-0-0-7873){ref-type="fig"}, co-culture of Teff cells with Treg cells led to a significantly prolonged Td (P\<0.05) in a manner that was independent of rhIL-6 presence. Regarding the proliferative capacity (Cp value) showed in [Fig. 6D](#f6-etm-0-0-7873){ref-type="fig"}, co-culture with Treg cells led to a significantly decreased Cp (P\<0.05) independent of rhIL-6 presence.

These results demonstrated that Treg cells exert suppressive effects on Teff cells in the presence or absence of rhIL-6. However, the inhibitory function of Treg cells may weaken in the presence of rhIL-6, which further suggests that increased numbers of Treg cells should be used for treatment considering the complexity of the internal environment of the patient.

Discussion
==========

As an important inhibitory immune cell subset *in vivo*, Treg cells have great potential in the immunotherapy of various diseases, including autoimmune diseases ([@b7-etm-0-0-7873]--[@b10-etm-0-0-7873]). Considering the complex internal environment of patients, e.g. inflammatory conditions, the stability and inhibitory function of Treg cells under such conditions should be further investigated.

Transplanting a sufficiently large number of Treg cells is a key factor for successful immunotherapy of diseases, including autoimmune diseases. Although Treg cells may be easily cultured and amplified *in vitro* in the presence of IL-2 and anti-CD3/CD8 beads ([@b19-etm-0-0-7873],[@b23-etm-0-0-7873],[@b28-etm-0-0-7873],[@b29-etm-0-0-7873]), the survival of Treg cells may be affected by inflammatory cytokines, including IL-6, *in vivo* ([@b30-etm-0-0-7873]--[@b33-etm-0-0-7873]). In the present study, the number of Treg cells cultured in the presence of 25 ng/ml rhIL-6 for 14 days was reduced by 49.7% when compared with that of cells cultured without rhIL-6, demonstrating the influence of the environment on Treg cell survival. Therefore, an increased number of Treg cells may be required for immunotherapy in patients with autoimmune diseases.

A sufficient number of Treg cells is the foundation of immunotherapy; more importantly, the stability and activity of Treg cells are directly associated with the effectiveness of treatment ([@b34-etm-0-0-7873]). In the present study, 56.0 or 24.7% of Treg cells expressed the transcription factor FoxP3 after *in vitro* culture for 14 days without or with rhIL-6, respectively. These results indicate that Treg cells are a relatively stable cell subset, but their stability declined significantly under inflammatory conditions, further suggesting that for immunotherapy, transplantation of increased numbers of Treg cells is required.

The expression of CD39 on the Treg cell membrane suggests increased activity of Treg cells ([@b25-etm-0-0-7873],[@b35-etm-0-0-7873]). In the present study, the proportion of CD39 expressed by FoxP3^+^Treg cells did not change with culture time, even in the presence of the inflammatory cytokine rhIL-6. These results suggest that FoxP3^+^ Treg cells may maintain their activity in an inflammatory environment. This result is also consistent with that of a previous study, which indicated that CD39^+^ Treg cells have a strong suppressive function even in the presence of inflammatory cytokines *in vitro* ([@b36-etm-0-0-7873]).

Suppression of Teff cell proliferation is an important aspect of the inhibitory function of Treg cells. In the present study, Treg cells suppressed the proliferation of Teff cells, which is consistent with the previous results regarding the stability and activity of Treg cells cultured for 5 days. A decreasing trend regarding Treg cell suppression was observed in the presence of rhIL-6. The inhibitory function of Treg cells is directly linked to the treatment effect of Treg cell-based immunotherapy.

The present study systematically examined the absolute count, stability, activity and inhibitory function of Treg cells, and possible changes in Treg cell function in the presence of cytokines that simulate inflammatory environments were determined *in vivo*. To achieve good efficacy, transplantation of increased numbers of Treg cells may be a reasonable therapeutic approach for immunotherapy. The present study provides an important experimental basis for the development of Treg cell-based immunotherapy for various immune-associated diseases, including autoimmune diseases.
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![Percentage of CD4^+^CD25^high^ Treg and CD4^+^CD25^−^ effector T cells. (A) Representative dot plots for the percentage of CD4^+^CD25^high^ Treg and CD4^+^CD25^−^ effector T cells in the lymphocyte population in PBMCs of a healthy donor. (B) Percentages of CD4^+^CD25^high^ Treg cells in the lymphocyte populations. (C) Percentages of CD4^+^CD25^−^ effector T cells in the lymphocyte populations. (D) Representative dot plots for the percentage of CD4^+^CD25^high^ Treg and CD4^+^CD25^−^ effector T cells in the CD4^+^ T lymphocyte population in PBMCs from a healthy donor. (E) Percentages of CD4^+^CD25^high^ Treg in the CD4^+^ T lymphocyte populations in PBMCs of healthy donors. (F) Percentages of CD4^+^CD25^−^ effector T cells in the CD4^+^ T lymphocyte populations in PBMCs from healthy donors. All values are expressed as the mean ± standard error of the mean (n=8). PBMCs, peripheral blood mononuclear cells; Treg cells, T-regulatory cells.](etm-18-04-2443-g00){#f1-etm-0-0-7873}

![Number of Treg cells cultured in the presence of different concentrations of rhIL-2 and anti-CD3/CD28 beads. (A) Number of all Treg cells after 3, 5, 7, 10 and 14 days of culture in the presence of anti-CD3/CD28 beads (Treg cells/beads, 1:1) and rhIL-2 (100, 300 or 500 U/ml). Values are expressed as the mean ± standard error of the mean (n=8). \*\*P\<0.01 and \*\*\*P\<0.0001, 100 vs. 300 U/ml rhIL-2 on the indicated days and ^\#\#^P\<0.01 and ^\#\#\#^P\<0.0001, 100 vs. 500 U/ml rhIL-2 on the indicated days. (B) Number of all Treg cells after 3, 5, 7, 10 and 14 days of culture in the presence of rhIL-2 (300 U/ml) and anti-CD3/CD28 beads (Treg cells/beads, 0.5:1, 1:1 or 2:1). Values are expressed as the mean ± standard error of the mean (n=8). \*P\<0.05 and \*\*P\<0.01, cells:beads 0.5:1 vs. 1:1 on the indicated days and ^\#^P\<0.05 and ^\#\#^P\<0.01, cells/beads 0.5:1 vs. 2:1 on the indicated days. rhIL, recombinant human interleukin; Treg cells, T-regulatory cells.](etm-18-04-2443-g01){#f2-etm-0-0-7873}

![Number of Treg cells following treatment with or without rhIL-6. Number of all Treg cells after culture for 3, 5, 7, 10 and 14 days in the presence of rhIL-2 (300 U/ml) and anti-CD3/CD28 beads (Treg cells/beads, 1:1) (n=8), without or with 25 ng/ml rhIL-6. Unpaired Student\'s t-test was used to compare differences between groups without and with rhIL-6. Values are expressed as the mean ± standard error of the mean (n=8). \*P\<0.05, Treg cells cultured for 7 days without vs. with rhIL-6 and \*\*P\<0.01, Treg cells cultured for 14 days without vs. with rhIL-6. rhIL, recombinant human interleukin; Treg cells, T-regulatory cells.](etm-18-04-2443-g02){#f3-etm-0-0-7873}

![Proportion of CD4^+^FoxP3^+^ Treg cells in all cell populations under inflammatory conditions. Percentages of CD4^+^FoxP3^+^ Treg cells among (A) all cell populations and (B) the FoxP3 MFI of CD4^+^FoxP3^+^ Treg cells after culture for 3, 5, 7, 10 and 14 days in the presence of rhIL-2 (300 U/ml) and anti-CD3/CD28 beads (Treg cells/beads, 1:1), with or without 25 ng/ml rhIL-6. Unpaired Student\'s t-test was used to compare differences between groups without and with rhIL-6. Values are expressed as the mean ± standard error of the mean (n=8). \*P\<0.05 vs. Treg cells cultured with rhIL-6. MFI, mean fluorescence intensity; Treg cells, T-regulatory cells; FoxP3, forkhead box P3; rhIL, recombinant human interleukin.](etm-18-04-2443-g03){#f4-etm-0-0-7873}

![Proportion of CD39^+^CD4^+^FoxP3^+^ active Treg cells in the CD4^+^FoxP3^+^ cell populations. Percentages of CD39^+^CD4^+^FoxP3^+^ active Treg cells among (A) the CD4^+^FoxP3^+^ Treg cells and (B) the CD39 MFI of CD39^+^CD4^+^FoxP3^+^ Treg cells after culture for 3, 5, 7, 10 and 14 days in the presence of rhIL-2 (300 U/ml) and anti-CD3/CD28 beads (Treg cells/beads, 1:1), with or without 25 ng/ml rhIL-6. Unpaired Student\'s t-test was used to compare differences between groups without and with rhIL-6. Values are expressed as the mean ± standard error of the mean (n=8). There was no statically significant differences were observed between the CD39 expression of the Treg cells between the two groups (P\>0.05). MFI, mean fluorescence intensity; Treg cells, T-regulatory cells; FoxP3, forkhead box P3; rhIL, recombinant human interleukin.](etm-18-04-2443-g04){#f5-etm-0-0-7873}

![Suppression of Treg cells under inflammatory conditions. (A) Representative histograms indicating the CFSE dilution from a sample cultured without rhIL-6 and a sample cultured with 25 ng/ml rhIL-6. The proliferation curve of Teff cells cultured alone (red) was overlaid with the curve for Teff cells co-cultured with Treg cells (blue). (B-D) The sorted Teff cells from healthy blood donors (n=8) were labelled with CFSE and co-cultured with sorted Treg cells (Teff cells/Treg cells, 2:1) in the presence of anti-CD3/CD28 beads (Teff cells/beads, 1:1), without or with 25 ng/ml rhIL-6. After co-culture for 5 days, Teff-cell proliferation was assessed by flow cytometry, and (B) the proportion of responding T-cells, (C) doubling time of a single T-cell and (D) proliferative capacity for the Teff cells were calculated. Paired Student\'s t-test was used to compare differences between groups without and with rhIL-6. Values are expressed as the mean ± standard error of the mean (n=8). \*P\<0.05 and \*\*P\<0.01 compared the doubling time of a single T-cell and proliferative capacity of Teff cells cultured for 5 days without vs. with Treg cells. Treg cells, T-regulatory cells; Teff cells, T effector cells; CFSE, 5,6-carboxyfluorescein succinimidyl ester; rhIL, recombinant human interleukin.](etm-18-04-2443-g05){#f6-etm-0-0-7873}
